

GENERAL REPORT FOR MONOGENIC DISEASES

SAMPLE

MALE

14:49:31 - 25/10/2020

NAME	RESULT
Hereditary hemochromatosis associated with HFE	Variant present
ARSACS (Autosomal recessive spastic ataxia of Charlevoix-Saguenay)	Variant absent
Acute intermittent porphyria	Variant absent
Agenesis of the Corpus Callosum with Peripheral Neuropathy (ACCPN)	Variant absent
Alpha-1 Antitrypsin Deficiency	Variant absent
Alpha-mannosidosis	Variant absent
Autosomal recessive polycystic kidney disease	Variant absent
Beta Thalassemia	Variant absent
Biotinidase deficiency	Variant absent
Birt-Hogg-Dube syndrome	Variant absent
Canavan Disease	Variant absent
Classical homocystinuria due to CBS deficiency	Variant absent
Congenital disorder of glycosylation type 1a (PMM2-CDG)	Variant absent
Congenital myasthenic syndrome	Variant absent
Cystic Fibrosis	Variant absent
Cystinosis	Variant absent
D-Bifunctional Protein Deficiency	Variant absent
Diastrophic dysplasia	Variant absent
Dihydrolipoamide Dehydrogenase Deficiency	Variant absent
Ehlers-Danlos Syndrome (EDS)	Variant absent
Familial Advanced/Delayed Sleep-Phase Syndrome	Variant absent
Familial Hypercholesterolemia	Variant absent
Familial Hypertrophic Cardiomyopathy (HCM)	Variant absent
Familial Mediterranean fever	Variant absent
Familial TTR-related amyloidosis	Variant absent
Familial Transthyretin Amyloidosis	Variant absent
Familial adenomatous polyposis	Variant absent

GENERAL REPORT FOR MONOGENIC DISEASES

SAMPLE

MALE

14:49:31 - 25/10/2020

Familial dysautonomia (Riley-Day syndrome)	Variant absent
Fanconi Anemia (FANCC-related)	Variant absent
GRACILE syndrome	Variant absent
Gaucher disease	Variant absent
Glucose-6-phosphate dehydrogenase deficiency(G6PD deficiency)	Variant absent
Glycogen storage disease type 1A (Von Gierke Disease)	Variant absent
Glycogen storage disease type 1B	Variant absent
Glycogen storage disease type 2 or Pompe Disease 1 & 2	Variant absent
Glycogen storage disease type 3	Variant absent
Glycogen storage disease type 5	Variant absent
Hereditary fructose intolerance	Variant absent
Hypokalemic Periodic Paralysis	Variant absent
Hypophosphatasia	Variant absent
Junctional Epidermolysis Bullosa	Variant absent
Leigh Syndrome, French-Canadian type (LSFC)	Variant absent
Leukoencephalopathy with vanishing white matter	Variant absent
Li-Fraumeni Syndrome	Variant absent
Limb-girdle muscular dystrophy	Variant absent
Malignant Hyperthermia	Variant absent
Maple syrup urine disease type 1B	Variant absent
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD)	Variant absent
Metachromatic leukodystrophy	Variant absent
Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency	Variant absent
Mucopolidosis IV	Variant absent
Mucopolidosis type II	Variant absent
Multiple endocrine neoplasia 2B	Variant absent
Neuronal Ceroid-Lipofuscinoses type 1 (associated to PPT1)	Variant absent
Neuronal Ceroid-Lipofuscinoses type 5 (associated to CLN5)	Variant absent

GENERAL REPORT FOR MONOGENIC DISEASES

SAMPLE

MALE

14:49:31 - 25/10/2020

Neuronal Ceroid-Lipofuscinoses type 6 (associated to CLN6)	Variant absent
Neuronal Ceroid-Lipofuscinoses type 7 (associated to MFSD8)	Variant absent
Niemann-Pick disease type A	Variant absent
Non-syndromic mitochondrial hearing loss	Variant absent
Pendred syndrome	Variant absent
Peters plus syndrome	Variant absent
Phenylketonuria	Variant absent
Pontocerebellar hypoplasia	Variant absent
Primary hyperoxaluria type 1 (PH1)	Variant absent
Primary hyperoxaluria type 2 (PH2)	Variant absent
Pyridoxine-dependent epilepsy	Variant absent
Refsum disease	Variant absent
Rhizomelic Chondrodysplasia Punctata Type 1	Variant absent
Salla Disease	Variant absent
Short chain acyl-CoA dehydrogenase deficiency (SCADD)	Variant absent
Sjögren-Larsson syndrome	Variant absent
Spinal muscular atrophy	Variant absent
Tay-Sachs disease	Variant absent
Tyrosinemia type I	Variant absent
Usher syndrome	Variant absent
Wilson disease	Variant absent
Zellweger syndrome	Variant absent

GENERAL REPORT FOR DRUGS

SAMPLE

MALE

14:49:31 - 25/10/2020

NAME	RESULT
Acenocoumarol and Phenprocoumon Metabolization	Intermediate metabolizer
Amitriptyline Metabolization	CYP2D6 Normal metabolizer/CYP2C19 Intermediate metabolizer
Celecoxib Metabolization	Intermediate metabolizer
Citalopram Metabolization	Intermediate metabolizer
Clomipramine Metabolization	CYP2D6 Normal metabolizer/CYP2C19 Intermediate metabolizer
Clozapine Metabolization	Ultrarapid metabolizer
Cyclosporine Metabolization	Poor Metabolizer
Diazepam Metabolization	Intermediate metabolizer
Disulfiram (Antabuse) and alcoholism	Sensitive to disulfiram
Escitalopram Metabolization	Intermediate metabolizer
Esomeprazole Metabolization	Intermediate metabolizer
Glipizide Metabolization	Intermediate metabolizer
Lansoprazole Metabolization	Intermediate metabolizer
Mercaptopurine Metabolization	Intermediate metabolizer
Metabolization of Clopidogrel	IM + high risk of non- efficacy
Metabolization of Prasugrel	Intermediate metabolizer
Metabolization of Ticagrelor	Intermediate metabolizer
Methotrexate response in arthritis	Inefficient response
Omeprazole Metabolization	Intermediate metabolizer
Pantoprazole Metabolization	Intermediate metabolizer
Phenytoin Metabolization	Intermediate metabolizer
Rabeprazole Metabolization	Intermediate metabolizer
Selection of Prasugrel, Ticagrelor and Clopidogrel in Cardiovascular Diseases	Intermediate metabolizer
Sertraline Metabolization	Intermediate metabolizer

GENERAL REPORT FOR DRUGS

SAMPLE

MALE

14:49:31 - 25/10/2020

Thiopurine methyltransferase enzyme activity	Intermediate metabolizer
Voriconazole Metabolization	Intermediate metabolizer
Warfarin Metabolization	Intermediate metabolizer
Abacavir hypersensitivity	Normal
Acetaldehyde toxicity	Normal
Aripiprazole Metabolization	Normal or extensive metabolizer
Brexiprazole Metabolization	Normal or extensive metabolizer
Carbamazepine Metabolization	Normal or extensive metabolizer
Cardiovascular diseases and response to pravastatin	Responds adequately to pravastatin
Codeine Metabolization	Normal or extensive metabolizer
Desipramine Metabolization	Normal or extensive metabolizer
Fluoropyrimidines Metabolization (Fluorouracil, Capecitabine, Tegafur)	Normal or extensive metabolizer
Fluorouracil toxicity	Normal
Fluoxetine Metabolization	Normal or extensive metabolizer
Fluvoxamine Metabolization	Normal or extensive metabolizer
Haloperidol Metabolization	Normal or extensive metabolizer
Hepatitis C response to treatment	Read technical report
Iloperidone Metabolization	Normal or extensive metabolizer
Irinotecan and colorectal cancer	Read technical report
Ivacaftor and Cystic Fibrosis	Does not present the disease

GENERAL REPORT FOR DRUGS

SAMPLE

MALE

14:49:31 - 25/10/2020

Methotrexate and side effects in rheumatoid arthritis	Common risk of adverse effects
Metoprolol Metabolization	Normal or extensive metabolizer
Mipomersen and familial hypercholesterolemia	No symptoms
Nortriptyline Metabolization	Normal or extensive metabolizer
Paroxetine Metabolization	Normal or extensive metabolizer
Perphenazine Metabolization	Normal or extensive metabolizer
Phenytoin sensitivity	Slightly increased sensitivity
Pimozide Metabolization	Normal or extensive metabolizer
Propranolol Metabolization	Normal or extensive metabolizer
Pseudocholinesterase deficiency	Read technical report
Response to Cyclophosphamide (and other chemotherapeutic agents) in breast cancer	Efficent response
Response to Valproic Acid and adverse effects	Tolerates VPA well
Risperidone Metabolization	Normal or extensive metabolizer
Statins and myopathy	Normal
Sulfonylurea metabolism	Slightly decreased sensitivity
Tacrolimus Metabolization in Transplants	Poor Metabolizer
Tramadol Metabolization	Normal or extensive metabolizer
Venlafaxine Metabolization	Normal or extensive metabolizer
Zuclopenthixol Metabolization	Normal or extensive metabolizer
Antidepressants and Blood-Brain Barrier	Input level of antidepressants to the brain slightly increased (improved response)

GENERAL REPORT FOR DRUGS

SAMPLE

MALE

14:49:31 - 25/10/2020

Antidiabetics Response (sulphonylureas)	Slightly decreased response
Aspirin and asthma	Increased risk
Aspirin and cardiovascular risk	Normal
Aspirin and colorectal cancer	Chemoprophylaxis with Aspirin may be beneficial
Asthma and inhaled corticosteroids	Read technical report
Cabozantinib response and medullary thyroid cancer	Does not respond to treatment
Caffeine metabolism	Fast metabolizer
Cisplatin response	Read technical report
Donepezil Metabolization (applicable to Galantamine)	Normal or extensive metabolizer
Fentanyl Metabolization	Poor Metabolizer
Gemcitabine Response in pancreatic cancer	Diminished response
Glimepiride, Glyburide and Glicazide Metabolization	Intermediate metabolizer
High blood pressure treatment with common drugs	It is better to treat with calcium channel blockers drugs
Metformin response	Increased response
Paclitaxel (chemotherapy) and development of neuropathies	Increased neuropathy risk
Paclitaxel Metabolization (chemotherapy) and toxicity	Intermediate metabolizer (significantly increased toxicity)
Palonosetron Metabolization	Normal or extensive metabolizer
Post-operative nausea and vomiting	Increased risk of postoperative nausea and vomiting
Response to Chlorthalidone	Better response

GENERAL REPORT FOR DRUGS

SAMPLE

MALE

14:49:31 - 25/10/2020

Response to olaparib in breast and ovarian cancer	Does not respond to olaparib
Response to -blockers (Metoprolol, Carvedilol, Propranolol)	Usual response
Risperidone Response	Normal response to risperidone
Tamoxifen Metabolization in Breast Cancer (Prognosis)	Intermediate metabolizer
Tolbutamide Metabolization	Intermediate metabolizer
Ziprasidone Response	Responds better than usual to ziprasidone
Acenocoumarol and Phenprocoumon Response	Normal sensibility
Adjuvant chemotherapy in primary breast cancer. Trastuzumab (Herceptin)	Adjuvant chemotherapy resistance
Atenolol Response	Increased response
Bevacizumab response in Colorectal Cancer	Increased response
Bleomycin and Testicular (germ cell) Cancer	Normal
Bupropion (Zyban)	Bupropion is more efficient
Carbamazepine and side effects	Normal
Carisoprodol Metabolization	Intermediate metabolizer
Clobazam Metabolization	Intermediate metabolizer
Cyclophosphamide Toxicity (and other chemotherapeutic agents)	Common side effects
Duloxetine Response	Slightly better than normal response to duloxetine
Floxacin toxicity	Normal
Fluoxetine, Citalopram and Escitalopram Response	High response
Gefitinib and lung cancer	Normal
Gemcitabine and pancreatic cancer	Usual response
Iloperidone and prolongation of the QTc interval	Probable risk of QT interval prolongation
LUM/IVA and Cystic Fibrosis	It does not present the deletion. Treatment not recommended

GENERAL REPORT FOR DRUGS

SAMPLE

MALE

14:49:31 - 25/10/2020

Methotrexate and response to transplants	Increased risk of rejection
Methotrexate and side effects in cancer treatment	Slightly increased risk of adverse effects
Mirtazapine Response	High response to mirtazapine
Naltrexone and alcoholism	Normal
Nelfinavir Metabolization (HIV)	Intermediate metabolizer
Olanzapine and weight gain	Much more likely
Opioids Response (Morphine, Oxycodone and Fentanyl)	Increased response
Paclitaxel Response (chemotherapy)	Diminished response
Response to Furosemide and Torasemide	Diminished response
Response to Hydrochlorothiazide	Better response
Response to Lithium in Bipolar Disorder	Effective response
Response to imatinib	Respond to treatment
Risperidone and weight gain	Normal
Rosiglitazone response in diabetics	Increased response to Rosiglitazone
Simvastatin Metabolization	Normal or extensive metabolizer
Venlafaxine Response	Elevated response to venlafaxine
Vincristine Response	Increased relapse risk
Warfarin Response	Normal sensitivity to Warfarine
Alfentanil Response	Efficient response
Antipsychotics and weight gain (amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, quetiapine, risperidone, ziprasidone, paliperidone)	Slight increased risk of weight-gain
Aspirin resistance and prothrombotic effect	Normal
Bisoprolol Response	Efficient response
Bupropion and Side Effects	Side effects slightly diminished

GENERAL REPORT FOR DRUGS

SAMPLE

MALE

14:49:31 - 25/10/2020

COPD treatment (Combined corticosteroid + B2 agonist treatment)	Better response
Carvedilol Metabolization	Normal or extensive metabolizer
Docetaxel and Leukopenia/neutropenia	Increased risk
Gemcitabine Response in breast cancer	Ineffective response
Gemcitabine Response in mesothelioma	Efficient response
Gemcitabine Response in non-small cell lung cancer	Ineffective response
Gemcitabine Toxicity in pancreatic cancer	Increased risk of toxicity
Hypersensitivity to Vaccination	Some possibility of adverse reaction
Iloperidone response	Efficient response
Methadone. Heroin addiction	Normal
Montelukast metabolization	Fast metabolizer
Montelukast response	Diminished response
Morphine and adverse effects	Slightly increased risk of side effects
Nelfinavir Response (HIV)	Increased response
Olanzapine and schizophrenia	Normal
Paclitaxel (chemotherapy) and development of hematotoxicity	Hematotoxicity risk slightly increased
Quetiapine Metabolization	Normal or extensive metabolizer
Response to Acetylcholinesterase Inhibitors (ChEIs) in Alzheimer's disease (galantamine, donepezil, rivastigmine)	Better response
Sexual dysfunction in response to SSRIs	Increased risk
Sildenafil (Viagra) Response	Increased response
Vincristine Metabolization	Poor Metabolizer
Vincristine and adverse effects	Protective effect against side effects
Voriconazole and cell transporters	Decreased plasma levels

GENERAL REPORT FOR COMPLEX DISEASES

SAMPLE

MALE

14:49:31 - 25/10/2020

HIGH RISK NAME	YOUR RISK	AVERAGE RISK	COMPARED TO AVERAGE
Asthma	12.54 %	4.9 %	2.56x
Coronary heart disease	4.36 %	3.3 %	1.32x
Schizophrenia	3.03 %	2.5 %	1.21x
Rheumatoid Arthritis	0.49 %	0.38 %	1.29x
Melanoma	0.04 %	0.03 %	1.26x
Bipolar disorder	< 0.01 %	< 0.01 %	2.38x
Cerebrovascular Accident			1.62x
Bladder cancer			1.73x
Thyroid cancer			1.33x
Osteoarthritis of the knee			1.22x
Atrial fibrillation			1.34x
Non-alcoholic fatty liver disease (NAFLD)			1.79x
Herniated Disc			1.43x
Cannabis-induced psychosis			1.8x
Sudden cardiac arrest			1.54x

GENERAL REPORT FOR COMPLEX DISEASES

SAMPLE

MALE

14:49:31 - 25/10/2020

REDUCED RISK

NAME	YOUR RISK	AVERAGE RISK	COMPARED TO AVERAGE
High blood pressure	22.62 %	43.5 %	0.52x
Obesity	2.7 %	10.8 %	0.25x
Heart attack	2.24 %	3.3 %	0.68x
Restless leg syndrome	1.94 %	4.5 %	0.43x
Gout	0.85 %	3.7 %	0.23x
Diabetes Mellitus, Type 2	0.84 %	4.22 %	0.2x
Diabetes Mellitus, Type 1	0.08 %	0.1 %	0.79x
Glioma	< 0.01 %	< 0.01 %	0.57x
Neuroblastoma	< 0.01 %	< 0.01 %	0.73x
Prostate cancer	< 0.01 %	0.15 %	0.08x
Amyotrophic lateral sclerosis	< 0.01 %	< 0.01 %	0.48x
Macular degeneration, age-related	< 0.01 %	< 0.01 %	0.15x
Parkinson's disease	< 0.01 %	< 0.01 %	0.53x
Systemic lupus erythematosus (SLE)	< 0.01 %	< 0.01 %	0.3x
Fuch's dystrophy			0.31x
Meningioma			0.4x
Multiple sclerosis			0.6x
Myelofibrosis (Myeloproliferative Neoplasms-MPNs)			0.04x
Primary biliary cirrhosis (PBC)			0.17x
Dyslexia			0.66x
Chronic obstructive pulmonary disease (COPD)			0.68x
Hyperuricemia			0.41x

GENERAL REPORT FOR COMPLEX DISEASES

SAMPLE

MALE

14:49:31 - 25/10/2020

Sjögren syndrome	0.71x
Celiac disease	0.59x
Autism	0.5x
Vitiligo	0.1x
Grave's disease	0.47x
Craniofacial anomalies (CFA).	0.77x
Cleft lip and/or cleft palate	
Basal cell carcinoma	0.66x
Chronic lymphocytic leukemia	0.78x
Exfoliative glaucoma	0.22x
Priapism in Sickle Cell Anemia	0.59x
Primary open-angle glaucoma	0.42x
Hypertriglyceridemia	0.62x
Selective deficiency of IgA	0.76x
Eosinophilic esophagitis (EoE)	0.75x
Limited cutaneous scleroderma	0.78x
Essential tremor	0.59x
Idiopathic membranous nephropathy	0.6x
Osteoarthritis of the hip	0.63x

GENERAL REPORT FOR COMPLEX DISEASES

SAMPLE

MALE

14:49:31 - 25/10/2020

NAME	YOUR RISK	AVERAGE RISK	COMPARED TO AVERAGE
Intracranial aneurysm	2.02 %	2.0 %	1.01x
Ankylosing spondylitis (AS)	0.89 %	1.0 %	0.89x
Crohn's disease	0.19 %	0.22 %	0.86x
Colorectal cancer	0.06 %	0.06 %	1.05x
Lung cancer	0.04 %	0.04 %	1.01x
Testicular cancer	< 0.01 %	< 0.01 %	1.09x
Psoriasis			1.12x
Peripheral arterial hypertension disease			1.05x
Periodontitis			1.14x
Migraine			1.03x
Osteoporosis			0.86x
Depression			0.86x
Cataracts			1.01x
Allergic Asthma			0.91x
Hypothyroidism			1.0x
Ulcerative colitis			0.85x
Narcolepsy			0.84x
Non-Hodgkin's lymphoma			0.8x
Deep vein thrombosis			0.86x
Esophageal Cancer			0.82x
Pancreatic cancer			1.06x
Pulmonary Fibrosis			0.92x
Biliary calculus or gallstones			0.9x
Atopic Asthma			1.04x

GENERAL REPORT FOR COMPLEX DISEASES

SAMPLE

MALE

14:49:31 - 25/10/2020

Seasonal affective disorder	0.92x
Abdominal Aortic Aneurysm	1.01x
Chronic kidney disease	1.11x
Anorexia nervosa	0.96x
Cluster headache	1.17x
Oral & Pharynx Cancer (Throat cancer)	1.03x
Myasthenia gravis	1.17x
Sarcoidosis	0.84x
Aperger's syndrome	0.97x
Multiple myeloma	1.09x
Progressive supranuclear palsy	1.05x
Stomach cancer	0.87x
Glioblastoma	1.06x

ANCESTRY

SAMPLE

MALE

14:49:31 - 25/10/2020

EUROPE	99.2
WEST & SOUTH EUROPE	34.00
West Europe	34.00
Multiple Backgrounds - Ashkenazi Jews	0.0
France - French	0.1
France - French: Basque	0.0
Germany - German	33.9
South Europe	0.0
Greece - Greek	0.0
Italy - Italian	0.0
Italy - Italian: Sardinian	0.0
Croatia - Croatian	0.0
Spain / Portugal - Iberian	0.0
NORTH & EAST EUROPE	65.20
North Europe	65.20
Sweden - Swedish	5.6
Great Britain - British	58.5
Finland - Finn	1.1
East Europe	0.0
Ukraine - Ukrainian	0.0
Russia - Russian	0.0

ANCESTRY

SAMPLE

MALE

14:49:31 - 25/10/2020

AMERICA	0.0
SOUTH AMERICA	0.0
West South America	0.0
Peru - Peruvian: Native population / Mixed population	0.0
Northern South America	0.0
Colombia - Colombian: Native population / Mixed population	0.0
Brazil	0.0
Brazil - Brazilian: Karitiana / Surui people	0.0
NORTH AMERICA	0.0
Southern North America	0.0
Mexico - Mexican: Pima people	0.0
Mexico - Mexican: Maya people	0.0

ANCESTRY

SAMPLE

MALE

14:49:31 - 25/10/2020

AFRICA	0.0
SOUTH & EAST AFRICA	0.0
South Africa	0.0
South Africa - South African: Bantu people	0.0
East Africa	0.0
Kenya - Kenyan: Bantu people	0.0
Ethiopia - Ethiopian	0.0
WEST AFRICA	0.0
Gambia - Gambian: Mandinka people	0.0
Senegal - Senegalese: Mandinka people	0.0
Nigeria - Nigerian: Esan people	0.0
Sierra Leona - Sierra Leonean: Mende people	0.0
SOUTH & CENTRAL HUNTER-GATHERER	0.0
Central H-G	0.0
Central African Republic - Central African: Aka people	0.0
Democratic Republic of the Congo - Congolese: Mbuti people	0.0
South H-G	0.0
Namibia - Namibian: San people or Bushmen	0.0

ANCESTRY

SAMPLE

MALE

14:49:31 - 25/10/2020

EAST ASIA	0.0
NORTHEAST ASIA	0.0
Japan - Japanese	0.0
SOUTHEAST ASIAN	0.0
Vietnam - Vietnamese: Kinh people	0.0
Cambodia - Cambodian: Khmer people	0.0
SIBERIA	0.0
Central Siberia	0.0
Russia - Russian: Yakut people	0.0
GREATER CHINA	0.0
China - Chinese: Dai people	0.0
China - Chinese: Naxi/Tu/Yi people	0.0
China - Chinese: Daur/Hezhen/Oroquen people	0.0
China - Chinese: Han/Miaozu/She people	0.0
CAUCASUS & CENTRAL ASIA	0.0
CENTRAL ASIA	0.0
Pakistan - Pakistani: Hazara people	0.0
China - Chinese: Uygur people	0.0
Uzbekistan - Uzbek	0.0
CAUCASUS	0.0
Armenia - Armenian	0.0
Georgia - Georgian	0.0
Russia - Russian: Adyghe people	0.0

ANCESTRY

SAMPLE

MALE

14:49:31 - 25/10/2020

NORTH AFRICA & MIDDLE EAST 0.0**MIDDLE EAST 0.0**

Multiple Backgrounds - Middle East Jews 0.0

Turkey - Turkish 0.0

Qatar - Qatari 0.0

Israel - Israeli: Druze people 0.0

Israel - Israeli: Palestinian people 0.0

Israel - Israeli: Bedouin people 0.0

NORTH AFRICA 0.0

Morocco - Moroccan 0.0

Egypt - Egyptian 0.0

Algeria - Algerian: Mozabite people 0.0

OCEANIA 0.0**MELANESIA 0.0**

Papua New Guinea - Papua New Guinean: Papuan people 0.0

SOUTH ASIA 0.8**INDIAN SUBCONTINENT 0.80**

Bangladesh - Bangladeshi: Bengali people 0.0

Pakistan - Pakistani: Balochi/Brahui/Makrani people 0.0

Pakistan - Pakistani: Burusho people 0.0

Pakistan - Pakistani: Kalash people 0.8

Pakistan - Pakistani: Pathan / Sindhi people 0.0

Sri Lanka - Sri Lankan: Tamil people 0.0

India - Indian: Gujarati people 0.0

India - Indian: Telugu people 0.0

GENERAL REPORT FOR TRAITS

SAMPLE

MALE

14:49:31 - 25/10/2020

NAME	RESULT
Ability to eliminate harmful substances	Normal
Adipose tissue formation	Decreased
Aggressive Prostate Cancer	Increased risk
Alcohol Addiction	Read technical report
Alcohol Flush Reaction	Do not show reaction
Antioxidant capacity	Normal
Biological Ageing	Read technical report
Birth Weight	Read technical report
Bitter Taste Perception	You may perceive the bitter taste
Blood Glucose	93 mg/dl (average)
Blood Glucose In Obese Children	Increased insulin resistance
Caffeine Consumption	Increased consume
Childhood Obesity Measurements	Read technical report
Diet Response	Read technical report
Drug Abuse	Typical risk
Duffy Antigen (Malaria Resistant)	Probably no resistant
Error Avoidance Capacity	Increased capacity
Exercise-induced muscle damage (initial phase)	Normal risk
Exercise-induced muscle damage (regeneration capacity)	Slower regeneration
Exercise-induced muscle damage (second phase)	Protective effect
Eye Color	Probably dark eyes
Freckles	Typical
Gambling behaviour	Increased odds of gambling
Glucose Tolerance Response With Exercise	Tolerance improvement
HDL Cholesterol Levels	Normal
Hair Color: Blond Hair	Read technical report

GENERAL REPORT FOR TRAITS

SAMPLE

MALE

14:49:31 - 25/10/2020

Hair Color: Red Hair	Read technical report
Hair Texture	Read technical report
Heroin Addiction	Typical risk
Intelligence Measurements	IQ increase
LDL Cholesterol Levels	Normal
Lactose Intolerance	Probably tolerant
Longevity	Read technical report
Malaria Complications	Slight protection
Male baldness	Increased risk
Memory	Read technical report
Muscle Endurance	Probably sprinter
Nicotine Addiction	Read technical report
Nicotine Dependence And Adolescence	Increased risk
Norovirus resistance	Susceptible
Obesity Measurements	Increased BMI
PSA (Prostate-specific Antigen) Levels	Less
Pain Sensitivity	Typical
Persistence Of Fetal Hemoglobin	No persistent
Photic Sneeze Reflex	Typical
Pigmented Rings On The Iris	Typical grade
Preference For Sweets	Increased
Preterm birth	Increased probability
QT Intervals	More prolonged
Response To Exercise	Read technical report
Sex hormone regulation	Read technical report
Smell, The Sense Of (Olfaction)	Read technical report
Stature	Read technical report
Tendinopathies in lower extremities (legs)	Increased risk
Tendinopathies in upper extremities (arms)	Normal risk
Vitamin D levels	Slightly less